Bidirectional association between atopic dermatitis, conjunctivitis, and other ocular surface diseases: A systematic review and meta-analysis
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Background: Conjunctivitis and several other ocular surface diseases (OSDs) have been linked to atopic dermatitis (AD) and its treatment. Objectives: To examine the association between AD, conjunctivitis, and other OSDs. Methods: A systematic review and meta-analysis was performed. Two authors independently searched EMBASE, PubMed, SCOPUS, and Web of Science and performed title/abstract and full-text review and data abstraction. Pooled random-effects prevalence and odds ratios (ORs) with 95% confidence intervals (CIs) were estimated. Results: The search yielded 5719 nonduplicate articles; 134 were included in the quantitative analysis. AD was associated with conjunctivitis compared to reference individuals (OR, 2.78; 95% CI, 2.33-3.32); the prevalences of conjunctivitis in patients with AD and reference individuals were 31.7% (95% CI, 27.7-35.9) and 13.3% (95% CI, 11.0-15.7), respectively. Keratoconus (OR, 3.71; 95% CI, 1.99-6.94) and ocular herpes simplex (OR, 3.65; 95% CI 2.04-6.51) were also associated with AD. Limitations: Disease definitions differed and often relied on self-reports. Few studies provided data concerning AD phenotype or OSDs other than conjunctivitis. Conclusions: Conjunctivitis is the most common ocular comorbidity in AD. Signs and symptoms of conjunctivitis and other OSDs in AD may be underreported, making proactive inquiry and examination by physicians treating patients with AD important.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Journal of the American Academy of Dermatology |
| Vol/bind | 85 |
| Udgave nummer | 2 |
| Sider (fra-til) | 453-461 |
| Antal sider | 9 |
| ISSN | 0190-9622 |
| DOI | |
| Status | Udgivet - 2021 |
Bibliografisk note
Funding Information:
Funding sources: Drs Thyssen and Halling are supported by an unrestricted grant from the Lundbeck Foundation .
Funding Information:
Funding sources: Drs Thyssen and Halling are supported by an unrestricted grant from the Lundbeck Foundation.Dr Loft has been an honorary speaker for Eli Lilly and Jansen Cilag. Dr Heegaard has attended advisory boards for Sanofi-Genzyme and received speaker honoraria from LEO Pharma, Sanofi-Genzyme, Santen, and Thea. Dr Kolko has a collaborative grant with LEO Pharma and Thea Pharmaceuticals, received speaker honoraria from Santen and Thea Pharmaceuticals, attends advisory boards for Allergan and Santen, and is a consultant for Thea Pharmaceuticals. Dr Egeberg has received research funding from Pfizer, Eli Lilly, Novartis, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation and honoraria as a consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, and Janssen Pharmaceuticals. Dr Silverberg has received honoraria as an advisory board member or consultant from AbbVie, Anaptysbio, Asana, Eli Lilly, Galderma, GlaxoSmithKline, Kiniksa, Leo, Menlo, Pfizer, Regeneron-Sanofi, Realm, and Roivant and as a speaker for Regeneron-Sanofi. Dr Thyssen has attended advisory boards for AbbVie, Eli-Lilly & Co, LEO Pharma, Regeneron, Sanofi-Genzyme, and Pfizer; received speaker honoraria from LEO Pharma, Regeneron, AbbVie, and Sanofi-Genzyme; and has been an investigator for AbbVie, Eli-Lilly & Co, Leo Pharma, Sanofi-Genzyme, and Pfizer. Drs Ravn, Ahmadzay, Christensen, Larsen, R?vdal, and Halling have no conflicts of interest to disclose.
Publisher Copyright:
© 2020 American Academy of Dermatology, Inc.
ID: 380159174